SUSTAIN trial programme: difference between revisions
Diff·revision 2 → 3·21:36, 2 Aug 2024
Difference between revision 2 and revision 3 of SUSTAIN trial programme. 12 lines changed; the page grew by 732 bytes.
| Revision 2 — 03:53, 18 Jul 2024 NNT_Nerys (talk) add the number randomised and the number completing 1,214 bytes ±0 | Revision 3 — 21:36, 2 Aug 2024 ForestPlotFinn (talk) add the run-in period, which changes how the baseline reads 1,946 bytes +732 | ||
|---|---|---|---|
| 10 | Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in [[STEP trial programme|STEP]].{{r|sorli2017}} | 10 | Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in [[STEP trial programme|STEP]].{{r|sorli2017}} |
| 11 | 11 | ||
| + | 12 | == Structure of the programme == | |
| + | 13 | | Trial | Comparator | Principal finding | | |
| + | 14 | |---|---|---| | |
| + | 15 | | SUSTAIN 1 | Placebo | HbA1c −1.5% at 1.0 mg | | |
| + | 16 | | SUSTAIN 2 | Sitagliptin | Greater HbA1c and weight reduction | | |
| + | 17 | | SUSTAIN 3 | Exenatide extended-release | Greater HbA1c and weight reduction | | |
| + | 18 | | SUSTAIN 4 | Insulin glargine | Greater HbA1c reduction, weight loss vs gain | | |
| + | 19 | | SUSTAIN 6 | Placebo, CV outcomes | MACE HR 0.74 (0.58–0.95) | | |
| + | 20 | | SUSTAIN 7 | [[Dulaglutide]] | Greater HbA1c and weight reduction | | |
| + | 21 | ||
| + | 22 | Active-comparator trials are more informative than placebo trials for a class with several members, and SUSTAIN 7 is one of relatively few head-to-head comparisons within the [[GLP-1 receptor agonist|GLP-1 class]].{{r|sorli2017}} | |
| + | 23 | ||
| 12 | == References == | 24 | == References == |
| 13 | {{reflist}} | 25 | {{reflist}} |